Lijie Xing

1.0k total citations
49 papers, 669 citations indexed

About

Lijie Xing is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Lijie Xing has authored 49 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 25 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Lijie Xing's work include Multiple Myeloma Research and Treatments (27 papers), CAR-T cell therapy research (14 papers) and Protein Degradation and Inhibitors (11 papers). Lijie Xing is often cited by papers focused on Multiple Myeloma Research and Treatments (27 papers), CAR-T cell therapy research (14 papers) and Protein Degradation and Inhibitors (11 papers). Lijie Xing collaborates with scholars based in China, United States and Taiwan. Lijie Xing's co-authors include Kenneth C. Anderson, Yu‐Tzu Tai, Shih‐Feng Cho, Liang Lin, Tengteng Yu, Kenneth Wen, Nikhil C. Munshi, Phillip A. Hsieh, Yuyin Li and Jiye Liu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer.

In The Last Decade

Lijie Xing

44 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lijie Xing China 14 393 364 336 176 136 49 669
Homer Adams United States 10 401 1.0× 401 1.1× 249 0.7× 237 1.3× 195 1.4× 25 713
Grégory Ehx Belgium 16 213 0.5× 262 0.7× 270 0.8× 294 1.7× 31 0.2× 39 696
Cyril Šálek Czechia 14 275 0.7× 201 0.6× 243 0.7× 311 1.8× 25 0.2× 47 728
Jenny Craigen United Kingdom 8 375 1.0× 317 0.9× 202 0.6× 197 1.1× 232 1.7× 11 660
Valentina Marchica Italy 14 234 0.6× 226 0.6× 182 0.5× 113 0.6× 20 0.1× 36 432
Huaijian Guo Canada 8 236 0.6× 148 0.4× 166 0.5× 492 2.8× 55 0.4× 11 661
Tengteng Yu China 13 330 0.8× 340 0.9× 280 0.8× 142 0.8× 123 0.9× 44 555
Weiqing Jing United States 15 452 1.2× 248 0.7× 225 0.7× 479 2.7× 27 0.2× 29 825
Karel Fostier Belgium 13 194 0.5× 141 0.4× 455 1.4× 263 1.5× 24 0.2× 25 738
Kimberly H. Harrington United States 11 492 1.3× 307 0.8× 343 1.0× 206 1.2× 254 1.9× 17 807

Countries citing papers authored by Lijie Xing

Since Specialization
Citations

This map shows the geographic impact of Lijie Xing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lijie Xing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lijie Xing more than expected).

Fields of papers citing papers by Lijie Xing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lijie Xing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lijie Xing. The network helps show where Lijie Xing may publish in the future.

Co-authorship network of co-authors of Lijie Xing

This figure shows the co-authorship network connecting the top 25 collaborators of Lijie Xing. A scholar is included among the top collaborators of Lijie Xing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lijie Xing. Lijie Xing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Guoliang, Ruiqi Zhang, Zhe Sun, Lijie Xing, & Yu Zhang. (2025). DSDIR: A Two-Stage Method for Addressing Noisy Long-Tailed Problems in Malicious Traffic Detection. 1–5. 1 indexed citations
2.
3.
Xia, Yin, Dan Liu, Hui Wang, et al.. (2025). Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study. Cancer. 131(1). e35697–e35697. 2 indexed citations
4.
Zhao, Hongyang, Lijie Xing, Linghao Zhang, et al.. (2025). Polymerase-based DNA reactions for molecularly computing cancerous diagnostic valences of multiple miRNAs. Journal of Nanobiotechnology. 23(1). 598–598.
5.
Liu, Dan, Hui Wang, Ping Li, et al.. (2025). Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma. Frontiers in Immunology. 16. 1697566–1697566.
6.
Lu, Ke, et al.. (2024). Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment. Frontiers in Oncology. 14. 1413494–1413494. 3 indexed citations
7.
Xing, Lijie, et al.. (2023). Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy. Cancers. 15(8). 2240–2240. 12 indexed citations
8.
Liu, Jiye, Lijie Xing, Teru Hideshima, et al.. (2022). Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma. Blood. 140(Supplement 1). 360–361. 1 indexed citations
9.
Robinson, Clifford G., Lijie Xing, Shahed N. Badiyan, et al.. (2022). 122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515). Annals of Oncology. 33. S88–S88. 3 indexed citations
10.
Xing, Lijie, Su Wang, Jiye Liu, et al.. (2021). BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clinical Cancer Research. 27(19). 5376–5388. 22 indexed citations
11.
12.
Lin, Liang, Shih‐Feng Cho, Lijie Xing, et al.. (2020). Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 35(3). 752–763. 64 indexed citations
13.
Feng, Lili, Yiqing Cai, Mingchen Zhu, Lijie Xing, & Xin Wang. (2020). The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell International. 20(1). 110–110. 68 indexed citations
14.
Lin, Liang, Lijie Xing, Shih‐Feng Cho, et al.. (2019). Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma. Blood. 134(Supplement_1). 1811–1811. 2 indexed citations
15.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2018). Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment. Blood. 132(Supplement 1). 592–592. 23 indexed citations
16.
Liu, Jiye, Tianyu Song, Lijie Xing, et al.. (2018). A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 33(1). 171–180. 65 indexed citations
17.
Tai, Yu‐Tzu, Liang Lin, Lijie Xing, et al.. (2018). APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 33(2). 426–438. 66 indexed citations
18.
Lin, Liang, Lijie Xing, Chirag Acharya, et al.. (2017). CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo. Blood. 130. 3067–3067. 6 indexed citations
19.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2017). Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies. 6(4). 18–18. 11 indexed citations
20.
Wu, Xingmao, Liu H, Yuankui Wu, et al.. (2015). [CD22 signal abnormalities in the pathogenesis of immune related pancytopenia].. PubMed. 95(26). 2066–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Homer Adams Breakdown of academic impact, for papers by Grégory Ehx Breakdown of academic impact, for papers by Cyril Šálek Breakdown of academic impact, for papers by Jenny Craigen Breakdown of academic impact, for papers by Valentina Marchica Breakdown of academic impact, for papers by Huaijian Guo Breakdown of academic impact, for papers by Tengteng Yu Breakdown of academic impact, for papers by Weiqing Jing Breakdown of academic impact, for papers by Karel Fostier Breakdown of academic impact, for papers by Kimberly H. Harrington
Rankless by CCL
2026